Abivax shares rise on reassuring safety data for UC drug as NDA looms
Abivax’s late‑stage data on obefazimod show malignancies at rates consistent with ulcerative colitis background risk, easing prior cancer concerns and sending the stock up about 34%; the company reiterates plans to file an FDA NDA in Q4 2026, with a Crohn’s trial due mid‑2027 and roughly 37% of initial non‑responders achieving remission after ~10 months on 50 mg. Analysts like Jefferies call the update supportive but warn that generalist investors may still hesitate amid cancer risk, cash needs, and takeover chatter.
